Along the same lines, in non-small cell lung cancer (NSCLC), acquired resistance to Gefitinib / Erlotinib kinase inhibitors has also been associated with a secondary mutation of the gatekeeper Thr790 residue
of the epidermal growth factor receptor (EGFR).
His graduate work at Yale University involved making lots of mutations in the transmembrane region
of the epidermal growth factor receptor (EGFR) and collecting data on which mutations affected dimerization.
Regulation
of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6.
Dual targeting
of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy - refractory, advanced colorectal cancer.
Urokinase - type plasminogen activator receptor regulates a novel pathway of fibronectin matrix assembly requiring Src - dependent transactivation
of epidermal growth factor receptor.
In addition to causing proteins to be secreted through general pathways from the cell and pathways involving metalloproteases, PMA specifically causes activation
of an epidermal growth factor receptor (EGFR).
Multiple mechanisms collectively regulate clathrin - mediated endocytosis
of the epidermal growth factor receptor.
RNA interference screen identifies Usp18 as a regulator
of epidermal growth factor receptor synthesis.
Changes in cell junctions induced by inhibition
of epidermal growth factor receptor in oral squamous cell carcinoma cells.
One of the key metabolic alterations that takes place during EMT is that
of the epidermal growth factor receptor (EGFR) which is a pathway that regulates growth, survival, proliferation, and differentiation in mammalian cells.
They found higher levels of JAK1 in resistant tumors, which caused increased expression
of epidermal growth factor receptor (EGFR)-- a receptor tyrosine kinase that promotes cell proliferation.
About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member
of the epidermal growth factor receptor family).
Not exact matches
High total and saturated fat intake were associated with greater risk
of estrogen
receptor - and progesterone
receptor - positive (ER+PR +) breast cancer (BC), and human
epidermal growth factor 2
receptor - negative (HER2 --RRB- disease, according to a new study published April 9 in the Journal
of the National Cancer Institute.
Clinically important findings suggest that targeting the
epidermal growth factor receptor (EGFR) and the fibroblast
growth factor receptor (FGFR) cellular pathways may benefit thousands
of patients with this disease, according to the study published today in the journal PLOS Genetics.
Between 10 and 30 percent
of NSCLC cases are driven by mutations in the
epidermal growth factor receptor (EGFR) gene.
Researchers found that a combination
of drugs — one targeting
epidermal growth factor receptor (EGFR) and one targeting tumor necrosis
factor (TNF)-- effectively blocks the cancer from using TNF as an escape route.
By using a range
of tissue stains, they were able to assess levels
of oestrogen
receptor (ER), progesterone
receptor (PR) and HER2 — human
epidermal growth factor — in order to divide the samples into four subtypes.
«CRKII most likely regulates the stability
of mutated
epidermal growth factor receptors and drives cancer
growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U
of T. «We found that a combinatorial chemotherapy that inhibits those mutated
receptors and CRKII could be beneficial in treating lung cancer.»
Among patients with advanced non-small cell lung cancer without a mutation
of a certain gene (EGFR), conventional chemotherapy, compared with treatment using
epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression
of the cancer, but not with overall survival, according to a study in the April 9 issue
of JAMA.
Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma
of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.
Human
epidermal growth factor receptor 2 (HER2) is upregulated in a subset
of human breast cancers.
The analysis also found that Asian / Pacific Islander women were more likely to be diagnosed with another subtype
of breast cancer: so - called human
epidermal growth factor receptor 2 (HER2)- overexpressing breast cancer.
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University
of California, San Diego, have described for the first time the molecular mechanism
of cancer development caused by well - known «resistance» mutations in the gene called
epidermal growth factor receptor (EGFR).
The study, called «Molecular Determinants
of Drug - Specific Sensitivity for
Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling
of EGFR mutations found in lung cancer can elucidate their molecular mechanism
of action and consequently optimize the selection
of therapeutic agents to treat patients.
The advent
of therapies directed at tumors with mutations in
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and B - Raf proto - oncogene (BRAF) genes over the past decade have dramatically changed outcomes, he says.
Epidermal growth factor receptor (EGFR) signal transduction plays a major role in
growth, proliferation and differentiation
of mammalian cells.
But Raz and colleagues have found that TPRV1 is also expressed by epithelial cells
of the intestines, where it is activated by
epidermal growth factor receptor or EGFR.
Approximately 10 - 15 %
of Caucasian and 30 - 35 %
of Asian patients with NSCLC have a mutation in the
epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.
Josef Singer and Judith Fazekas, both lead authors
of the study, discovered that a
receptor frequently found on human tumor cells (
epidermal growth factor receptor or EGFR) is nearly 100 percent identical with the EGF
receptor in dogs.
Alice Shaw recalls a signal moment in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists discovered that mutations in a gene for
epidermal growth factor receptor (EGFR) were the culprits in about 10 to 15 percent
of lung cancer patients.
The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms
of resistance to tyrosine kinase inhibitor (TKI) drugs that target the
Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases
of non-small cell lung cancer (NSCLC).
PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial
of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone
Receptor Positive (HR +) / Human
Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer
An Open Label, Phase II Study
of Neratinib in Patients with Solid Tumors with Somatic Human
Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Inverse relationship between
epidermal growth factor receptor expression and radiocurability
of murine carcinomas.
Zhang, Y. and Wolf - Yadlin, A. and Ross, P. L. and Pappin, D. J. and Rush, J. and Lauffenburger, D. A. and White, F. M. (2005) Time - resolved mass spectrometry
of tyrosine phosphorylation sites in the
epidermal growth factor receptor signaling network reveals dynamic modules.
Aberrant epithelial morphology and persistent
epidermal growth factor receptor signaling in a mouse model
of renal carcinoma.
Targeting
of AMSH to endosomes is required for
epidermal growth factor receptor degradation.
Differential effects
of low - and high - dose GW2974, a dual
epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Growth factor receptor binding protein 2 - mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocy
Growth factor receptor binding protein 2 - mediated recruitment
of the RING domain
of Cbl to the
epidermal growth factor receptor is essential and sufficient to support receptor endocy
growth factor receptor is essential and sufficient to support
receptor endocytosis.
DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor
of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with
epidermal growth factor receptor (EGFR) mutations.
A major challenge for assessing driver mutations, such as
epidermal growth factor receptor (EGFR) mutations, in advanced disease is the scarcity
of suitable biopsy tissue for molecular testing.
Each subtype was classified by gene expression clustering, and showed specific patterns
of genetic alterations, particularly for four genes: platelet - derived
growth factor receptor alpha (PDGFRA), isocitrate dehydrogenase 1 (IDH1),
epidermal growfth
factor receptor (EGFR), and neurofibromin 1 (NF1).
Chemotherapy is a key part
of the standard treatment regimen for triple - negative breast cancer patients whose cancer lacks expression
of estrogen and progesterone
receptors and the human
epidermal growth factor receptor 2...
The
epidermal growth factor receptor (EGFR) pathway is a complex signaling cascade that is involved in the development and progression
of cancer.
Triple negative breast cancer is a type
of breast cancer that does not express
receptors for the hormones estrogen and progesterone, or for human
epidermal growth factor.
The human
epidermal growth factor receptor - 2 (HER2) gene makes proteins responsible for maintaining healthy cell
growth, division and repair
of breast tissue.
In addition to RIPK2 binding as part
of this computer - based (initial) screening, we selected compounds that inhibited
epidermal growth factor receptor (IC50 values > 1000 nM; weak inhibitory activity) along with weak binding interactions in the EGFR and c - ABL binding sites, two common off - targets for previously identified RIPK2 inhibitors.
Neutrophil - to - Lymphocyte Ratio Predicts Overall Survival
of Advanced Non-Small Cell Lung Cancer Harboring Mutant
Epidermal Growth Factor Receptor
The discovery
of how the
epidermal growth factor receptor (EGFR) is activated offers insight into how current EGFR - blocking drugs interact with the
receptor and an important avenue for the...
These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group
of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent
of node - negative, estrogen
receptor (ER)- positive, human
epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.